Combination therapy of Montelukast with Budesonide may be more effective than budesonide alone for treating chronic cough-variant asthma (CCVA) in children aged 4-11 years, according to a study published in the journal Medicine.
The study included 82 cases of children with CCVA, aged 4 to 11 years. The study participants received either montelukast combined budesonide (MCBor budesonide alone between May 2015 and April 2017. The primary outcome was lung function, measured by the peak expiratory flow rates (PEFRs) and forced expiratory volume in 1 second (FEV1). The secondary outcome was measured by the clinical assessment score. All outcomes were measured after 8-weeks. treatment.
The study found that after 8 weeks of treatment, the intervention group showed greater effectiveness in improving the lung function measured by PEFR and FEV1 compared with the control group. The intervention group showed better clinical assessment score vs placebo group. No serious adverse events were reported in both the groups.
According to the authors, the combination of montelukast and budesonide may help to manage the symptom control, lung function improvement, and may offer the narrow airway protection compared with inhaled corticosteroids alone.
The authors concluded that the results of the study demonstrate that the effectiveness of MCB is superior to budesonide alone in the treatment of children with CCVA and further, large sample size with longer treatment duration is warranted to determine the role of MCB in the treatment of CCV.
Cough-variant asthma is a type of asthma in which the main symptom is a dry, non-productive cough. Patients with cough-variant asthma often have no other common asthma symptoms, such as wheezing or shortness of breath.
For full information log on to https://insights.ovid.com/crossref?an=00005792-201807270-00033